Leerink Partners’ Post

Have you subscribed to the Argenica Therapeutics Investor Hub? Whether you're a current investor, future investor or you're just interested in learning more about the commercialisation of ARG-007, joining our Investor Hubs ensure you never miss an important piece of Company news. When you subscribe, you receive the following, direct to your inbox: ➡ ASX announcements ➡ Updates on news coverage relating to Argenica ➡ Important updates and relevant company information Learn more or join today: https://bit.ly/3UO305v #ASX #AGN #InvestorRelations #StrokeAwareness #InvestorNews #ARG007

Biotechs often face unpredictable resource fluctuations which impact how legal must operate and plan. During our recent webinar, Scott Akamine, Chief Legal Officer, Cerevel Therapeutics, highlighted that, throughout these fluctuations, the legal department must adapt and provide support to the rest of the organization. Meanwhile, Chris Moore, CLO at Umoja Biopharma, shared insights on efficient processes, and Karl DORWART, VP of Life Sciences at Factor, emphasized aligning legal strategy with business goals. Missed the webinar? Watch the replay here: https://ow.ly/MH5U50SOTL8

📊 Market Movers Update 📊 The market pulse throbs with contrasts - let's meet the leaders and laggards. Monte Rosa Therapeutics, Inc. has emerged as a significant front-runner, flaunting a boost of +93.87%. Simultaneously, Greenlane Holdings, Inc. and Porch Group, Inc. shone with +91.92% and +70.31% growth respectively, making their mark in the distribution services and technology sectors. On the flip side, entities like Dogness

🚀 Biotech IPO Surge Continues with Septerna's $157M Offering Septerna is set to enter the public market, raising $157M through its upcoming Nasdaq IPO, extending its financial runway into 2027. Backed by $150M from a recent Series B round, the company is developing oral GPCR-targeting drugs, with its lead candidate, SEP-786, in Phase 1 trials for hypoparathyroidism. With shares priced between $15-$17, this IPO adds to Septerna’s total capital of $294M, positioning it as a key player in rare disease treatment. 💡 📊 2024 Biotech IPO Market Raises Billions The biotech IPO market has seen significant activity in 2024, with more than 22 IPOs raising around $3.54 billion from January to October. This marks a stark contrast from the quiet markets of 2023, with notable IPOs like Upstream Bio, CAMP4 Therapeutics, and MBX Biosciences leading the charge. Investor enthusiasm is driving these offerings, signaling renewed confidence in the biotech sector, especially in areas like rare diseases, GPCR-targeting therapies, and innovative drug platforms. 📈 💰 Septerna's IPO: Timing Before Election Uncertainty As Septerna heads to the public markets, its IPO is expected to close just before the U.S. presidential election. This positioning is critical, as the market might see a slowdown in IPO activity toward the end of the year due to political and economic uncertainties surrounding fiscal and monetary policy changes. Despite the competitive landscape, Septerna is well-placed to capitalize on its innovative research and clinical programs, making it one of the last major biotech IPOs before year-end. 🌍 #BiotechIPO #Septerna #GPCR #DrugDevelopment #Pharmaceuticals #HealthcareInnovation #Investment #VentureCapital #IPO2024 #Nasdaq

Oxford Cannabinoid Technologies Holdings Plc is pleased to announce conditional Subscriptions for new Ordinary Shares to raise gross proceeds of £640,000 from existing Shareholders and new investors. We are also pleased to announce that we have entered into a term sheet for a convertible loan note with Cantheon Capital, LLC, existing OCTP Shareholders and OCTP directors, to raise up to £565,000 on execution of a binding agreement and subject to certain conditions. Cantheon Capital, LLC, a fund focused on listed biotech stocks with near term catalysts, will invest an aggregate amount of £450,000 to fund Oxford Cannabinoid Technologies Holdings Plc's Phase I clinical trial for OCT130401, our second programme focussing on the circa £1.8bn #TrigeminalNeuralgia market, which is anticipated to commence in Q2 2024 in Australia with potential for a further investment of circa £925,000 as part of OCT130401's Phase II trial with existing investors and OCTP directors contributing an additional £115,000.   The #Fundraise comprises gross proceeds of up to £1.205m (approximately £1.15m net of expenses) and will be used to further our work in Programmes 1 and 2 and provide working capital to the company. Clarissa Sowemimo-Coker, CEO of OCTP, said "Commencing Phase I Clinical Trials for OCT130401, OCTP's second programme focussing on the Trigeminal Neuralgia market, as well as starting the process of opening INDs for OCT461201 and OCT130401 are significant milestones for investors which we aim to achieve in relatively compressed timelines.   We are also very pleased to announce that Cantheon has selected OCTP as a growth stock in which it wishes to play a significant role as a cornerstone investor. Cantheon has an established track record of investments in mid-stage specialist biotech businesses, providing capital funding and scientific advice. This announcement represents an important vote of confidence in the Company and its pipeline, and a powerful endorsement of the progress the business is making. We are delighted to welcome Cantheon on board and look forward to working with them." https://lnkd.in/eyVWyr-S

Thoughts on this? >> ARCH, biotech's star slugger, snags another $3B for 13th fund >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #pharmaceutical #healthcare #biotech

Thoughts on this? >> ARCH, biotech's star slugger, snags another $3B for 13th fund >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharmaceutical #healthcare #pharma #biotech

🇺🇸📈The stocks with the highest growth for the week in the Russell 2000 index: ⠀   1. Rent the Runway, Inc. (#RENT) - +302.30%; 2. Alpine Immunce Sciences, Inc. (#ALPN) - +84.39%; 3. Acrivon Therapeutics, Inc. (#ACRV) - +54.17%; 4. Janux Therapeutics, Inc. (#JANX) - +49.91%; 5. Cartesian Therapeutics, Inc. (#RNAC) - +45.68%. 🇺🇸📉The stocks with the biggest decline over the week in the Russell 2000 index: 1. Tingo Group (#TIOG) - -52.67%; 2. Eyenovia, Inc. (#EYEN) - -40.45%; 3. Anita Medical, Inc. (#RCEL) - -35.80%; 4. Luminar Technologies, Inc. (#LAZR) - -35.00%; 5. Energy Vault Holdings, Inc. (#NRGV) - -33.53%. #RUT #USA #stock #StockMarket

Merck sees clear vision to new #ophthalmology assets with $3B EyeBio buy 💸Why we like this deal: ✅Upfront cash deal ✅$1.7 B in potential milestone payments ✅#Merck will acquire a pipeline of vision loss candidates, including lead asset #Restoret ✅#EyeBio will be positioned to benefit from the resources needed to support clinical, regulatory and commercial development of their drugs Read more from #FierceBiotech: https://buff.ly/4aPI1ny #ophalmology #eyehealth

Esperion Therapeutics (NASDAQ: ESPR) Stock Jumps on Upbeat Q1 Financial Report https://lnkd.in/dgvfr3rW $ESPR #Esperion #NASDAQ #stockmarket #stockmarketnews #BusinessNews #news #NewsAlert